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in 3 cases, and grade 3 in 3 cases). This early intervention and
appointment was feasible for each request, since patients were
selected to live no >80 km (1 h trip) from the hospital. No other
additional visit was needed, emphasizing the safety of the pro-
cedure. Overall 98% of the patients mentioned their preference
for home administration when compared with hospital adminis-
tration of s.c. bortezomib. Despite some limitations including
single-center design, a relatively small sample size, and a nonva-
lidated survey, our results indicate that the administration of the
first s.c. bortezomib dose per cycle (day 1 of each cycle) in the
outpatient department, followed by home administration pro-
vided by visiting nurses trained on the s.c. administration of
bortezomib and the management of side-effects represents a
safe and cost-effective procedure for patients treated for MM.
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Background: Adenoid cystic carcinoma (ACC) is a subtype of malignant salivary gland tumors (MSGT), in which 90% of
cases express cKIT. Dasatinib is a potent and selective inhibitor of five oncogenic protein tyrosine kinases (PTKs)/kinase
families including cKIT. We conducted a phase II study to determine the antitumor activity of dasatinib in ACC and non-ACC
MSGT.
Patients and methods: In a two-stage design, patients with progressive, recurrent/metastatic ACC (+cKIT) and non-ACC
MSGT (separate cohort) were treated with dasatinib 70 mg p.o. b.i.d. Responsewas assessed every 8 weeks using RECIST.
Results: Of 54 patients: 40 ACC, 14 non-ACC (1, ineligible excluded); M:F = 28 : 26, median age 56 years (range 20–82
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years), ECOG performance status 0 : 1 : 2 = 24 : 28 : 2, prior radiation: 44, prior chemotherapy: 21. The most frequent
adverse events (AEs) (as % of patients, worst grade 2 or higher) were: fatigue (28%), nausea (19%), headache (15%), lympho-
penia (7%), dyspnea (11%), alanine aminotransferase increased (7%), anorexia (7%), vomiting (7%), alkaline phosphatase
increased (6%), diarrhea (6%), neutropenia (6%), and noncardiac chest pain (6%). No grade 4 AE occurred, 15 patients
experienced a grade 3 AE, primarily dyspnea (5) and fatigue (4), and cardiac toxicity (1 prolonged QTc). Among ACC patients,
best response to dasatinib: 1 patient (2.5%) had partial response, 20 patients (50%) had stable disease (SD) (3–14 months),
12 patients (30%) had PD, 2 withdrew, 3 discontinued therapy due to AE, and 2 died before cycle 2. Median progression-
free survival was 4.8 months. Median overall survival was 14.5 months. For 14 assessable non-ACC patients, none had ob-
jective response, triggering early stopping rule. Seven had SD (range 1–7 months), 4 PD, 2 discontinued therapy due to AE,
and 1 died before cycle 2.
Conclusion: Although there was only one objective response, dasatinib is well tolerated, with tumor stabilization achieved
by 50% of ACC patients. Dasatinib demonstrated no activity in non-ACCMSGT.
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introduction
Malignant salivary gland tumors (MSGT) is a rare disease, com-
prised of a wide spectrum of histologic types, that represents
6%–7% of head and neck cancers and 2600 new cases per year
in the United States [1, 2]. Systemic chemotherapy is used in the
management of MSGT primarily for recurrent disease that is
not amenable to surgery or radiation therapy, or for metastatic
disease. The efficacy of conventional chemotherapy is generally
poor and is considered palliative. Reported overall response
rates range from 26% to 35% with median survival between 12.5
and 21 months [3–5]. Clinical studies utilizing conventional
chemotherapy have not clearly demonstrated improvement in
survival compared with supportive care alone; consequently, no
superior drug or drug combination has been identified. The
need to investigate new agents and molecularly targeted agents
is underscored by these facts.
Adenoid cystic carcinoma (ACC) is a common histologic
subtype of MSGT and represents between 10% and 40% of
MSGT and is characterized by late recurrences with distant me-
tastases occurring in roughly 37% of cases [1, 2, 6]. Metastatic
ACC may follow a natural history of indolent growth succeeded
by a more rapid growth phase. Expression of c-KIT ligand
appears to be common in ACC—reported in 80%–100% of
patients with ACC arising from salivary gland [7–9]. c-kit is a
proto-oncogene that encodes for a transmembrane cell surface
receptor, kit. cKIT is a member of the same subclass of genes
similar to platelet-derived growth factor and colony-stimulating
growth factor. Functional mutations of c-KIT have been asso-
ciated with the pathogenesis of a number of malignancies that
express c-KIT (e.g. gastrointestinal stromal tumors, mast cell
disease, and acute leukemia). Overexpression of c-KIT has been
postulated to be associated with molecular pathogenesis of ACC
[7–9]. Testing of this hypothesis in clinical trials using imatinib,
a potent inhibitory of tyrosine kinases of PDGF as well as the
receptor of kit, is feasible. However, detection of clinical
response in tumors that follow an indolent growth pattern has
been a barrier in trial design. Clinical trials that have examined
the activity of imatinib in ACC and failed to demonstrate signifi-
cant clinical efficacy have been limited by this problem. More
stringent selection of patients with documented detectable
tumor growth has been postulated to permit more accurate
detection of drug activity in ACC and has been reported by
Faivre et al. [10].
Dasatinib (BMS-354825) is an aminothiazole analog that is an
orally administered (p.o.) protein tyrosine kinase (PTK) inhibitor
and has specificity for five kinases/kinase families (BCRABL,
c-SRc, c-KIT, PDGFβ receptor, and EPHA2). In vitro, in vivo, and
early clinical trials demonstrate potent antiproliferative activity in
a wide spectrum of cancer cell lines/types, and patients with
chronic myelogenous leukemia (CML) and solid tumor patients
[11–13]. Dasatinib has also shown potent inhibition of vascular
endothelial growth factor- and basic fibroblast growth factor-
driven proliferation of human umbilical vein endothelial cells, with
IC50 values of 43 and 248 nM, respectively. Dasatinib appears to
have more potent antitumor effects compared with imatinib based
on studies with imatinib-resistant tumors, while other studies have
shown 500-fold greater potency than imatinib in inhibiting
BCRABL. Based upon the above information, we hypothesized
that dasatinib has potential clinical activity in ACC and, given its
broad mechanism of action, that it may have activity in other
MSGT. To test these hypotheses, we proposed a clinical trial with
the primary objective of examining clinical response to dasatinib in
ACC patients and an exploratory secondary objective of testing the
activity of dasatinib in non-ACCMSGT.
patients andmethods
patient eligibility
Two patient cohorts were enrolled in this study—patients with ACC and
those with non-ACC MSGT. Patients 18 years or older with histologically or
cytologically documented MSGT were eligible; ACC patients were required
to have c-kit-positive tumors determined by immunohistochemistry staining
performed at each participating institution using peroxidase–antiperoxidase
technique on 4-μM sections with antibody dilution of 1 : 10 (DAKO,
Carpinteria, CA). Sections were scored as positive for c-KIT expression if a
diffuse staining pattern was present as defined by ≥25% tumor cells staining
positive in cytoplasm and/or membrane.
Patients were required to have tumors that were not amenable to curative
surgery or radiation. In addition, patients were required to have radiograph-
ically measurable disease and evidence of tumor progression within
4 months before study registration. Patients were allowed to have unlimited
prior therapy so long as no chemotherapy, radiation, or major surgery was
administered within 4 weeks before registration; adequate performance
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status (ECOG 0–2); life expectancy >12 weeks, and normal organ function
defined as absolute neutrophil count more than 1500/μl, platelet count more
than 100 000/μl, total bilirubin within the institutional limit, aspartate ami-
notransferase and/or alanine aminotransferase ≤2.5 × institutional upper
limit of normal, creatinine within normal institutional limits, or creatinine
clearance ≥60 ml/min/1.73 m2 for patients with creatinine levels above the
institutional limit. Patients were excluded if they were taking another investi-
gational agent, had prior treatment with other targeted agents that inhibited
VEGFR, BCRABL, c-SRc, c-KIT, PDGFβ receptor, or EPHA; history of
QTc prolongation, serious ventricular arrhythmia; brain metastasis; serious
medical conditions such as nonhealing wounds, history of stroke within 12
months, history of myocardial infarction, arrhythmia, unstable angina,
congestive heart failure, or arterial bypass with 6 months; uncontrolled inter-
current illness; pregnant women or women who were breast-feeding; and
patients who had an active pleural or pericardial effusion.
therapy
Study treatment, administered in the outpatient setting, consisted of 70 mg
orally twice daily (total 140 mg/day). Dasatinib was provided by the National
Cancer Institute, Division of Cancer Treatment and Diagnosis, Cancer
Therapy Evaluation Program. Four weeks (28 days) constituted one cycle of
treatment and continued until disease progression, unacceptable toxicity,
patient’s refusal to continue, or physician’s decision to discontinue therapy.
toxicity assessments and dose reductions
Toxicity was graded according to Common Terminology Criteria for
Adverse Events (CTCAE) version 3.0. Three dose-level decreases were per-
mitted for patients who encountered toxicity: 50 mg twice daily, 100 mg in
AM daily (same dose as previous level but a different schedule), and 70 mg
in AM daily. Patients received therapy without interruption or dose modifi-
cation for grade 1 non-hematologic toxicity. For grade 2 toxicity, supportive
care was instituted and was continued unless, at the discretion of the phys-
ician for intolerable side-effects, treatment was held until toxicity resolved to
grade <2 and treatment resumed at the same dose or at a 30% reduction (to
50 mg b.i.d.). For grade 3 or 4 toxicity, dasatinib was held and supportive
therapy instituted until toxicity resolved to <grade 2, and therapy resumed at
a dose reduced to the next lower level. Patients were removed from therapy if
they failed to recover to grade 0–1 or tolerable grade 2 toxicity within 14
days of discontinuation of study drug overall response they experienced
agent-related AEs requiring dose modification despite three previous dose
reductions (i.e. would require a fourth dose reduction), unless the investiga-
tor and Cancer Therapy Evaluation Program senior investigator agreed that
the patient should remain on the study because of evidence that the patient
might continue deriving benefit from study treatment.
assessment of response
Patients were evaluated by imaging every 8 weeks for objective response
according to classification by Response Evaluation Criteria in Solid Tumor
Committee (RECIST) [14].
statistical considerations
The primary objective of the study was to determine response rate (complete
response plus partial response) and progression-free survival (PFS) for ACC
patients receiving dasatinib. Secondary objectives were to determine object-
ive response rate for non-ACC MSGT; and for both cohorts: duration of re-
sponse, stable disease rate; duration of stable disease, and overall survival.
The study also examined the safety and tolerability of dasatinib for all
patients. In the ACC cohort, a sample size of N = 40 patients was chosen,
which provided 85% power to detect an improvement in the median PFS
time from 2 months to a little over 4 months, based on a one-sided α level of
0.05. For the non-ACC cohort, a two-stage design was used to test the null
hypothesis that the response rate was 5% versus a 20% alternative. In order
to reduce the risk of exposure of patients to potentially futile therapy, an
early stopping rule was applied to both cohorts. For ACC patients, data were
analyzed after half (N = 20) patients were followed for 2 months. If the
observed PFS rate at 2 months was <50%, then accrual would be terminated
for futility. Based on the results of Wieand and Therneau, this leads to a
minimal power loss of <2% [15]. For the non-ACC cohort, 14 patients were
to be enrolled in the first stage; if no responses were observed, then accrual
in this cohort would be discontinued [16]. If one or more responses were
observed, then a total of 25 patients would be enrolled and the drug would
be considered promising for further investigation if at least three responses
were observed. This design has an α level of 0.12 and 88% power if the true
response rate is 20%.
results
patients and treatment
Between May 2009 and December 2011, 41 patients with ACC
and 14 patients with non-ACC MSGT were enrolled on to this
study from 14 centers in the United States and Canada. One
ACC patient was found to be ineligible and is excluded from
Table 1. Characteristics of patients with adenoid cystic carcinoma
and nonadenoid cystic carcinoma of the salivary gland
Characteristic ACC (N = 40) Non-ACC
(N = 14)
Age
Median 56 56
Min–max 30–82 20–71
N % N %
Sex
Male 18 45.0 10 71.4
Female 22 55.0 4 28.6
Zubrod
0 18 45.0 6 42.9
1 21 52.5 7 50.0
2 1 2.5 1 7.1
Ethnicity
Hispanic/Latino 2 5.0 0 0.0
African-American 1 2.5 3 21.4
Caucasian 35 87.5 11 78.6
Other 2 5.0 0 0.0
Prior RT 34 91.9 10 76.9
(Missing) (3) (1)
Prior chemotherapy 14 37.8 7 53.8
(Missing) (3) (1)
Prior surgery 31 83.8 9 69.2
(Missing) (3) (1)
Sites of metastases
Lung 35 87.5 9 64.3
Liver 13 32.5 4 28.6
Bone 10 25.0 5 35.7
No. of metastases
0 (recurrent disease) 2 5.0 4 28.6
1 23 57.5 5 35.7
2 10 25.0 2 14.3
3 5 12.5 3 21.4
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analysis. Patient characteristics are summarized in Table 1. All
patients had measurable disease as well as evidence of measur-
able tumor growth before study enrollment.
outcomes of non-ACC cohort
No objective responses were observed among the first 14
patients in the non-ACC cohort, thus accrual was halted to this
arm. Seven patients had stable disease, four had early disease
progression, and three discontinued therapy due to AEs before
the first response evaluation.
outcomes in ACC cohort
For the ACC cohort, data were analyzed after the planned first
stage of accrual; the observed PFS met the threshold of 50% at
2 months thus permitting continuation of accrual to this cohort.
One objective response was observed in ACC patients. The
duration of response was 3.25 months. Twenty patients (50%)
had stable disease. Three patients withdrew, one died, and four
came off therapy due to AEs before the first disease assessment;
these patients are all counted as non-responders. Objective re-
sponse as demonstrated by maximum tumor effect for target
lesions is shown in Figure 1. A total of 29 patients among the 40
ACC patients eventually experienced disease progression, 5 died
before disease progression, and 6 were censored (never pro-
gressed while on study). Five patients withdrew from therapy
due to toxicity. The earliest progression occurred at 0.9 months
and the last progression occurred at 31.7 months. Approximately
one quarter of the patients had stable disease for 1.8 months,
and approximately three quarters of patients had stable disease
for 7.4 months.
Median survival for ACC patients was 14.5 months. Six-month
survival rate was 81.5% [95% confidence interval (CI) 68.1% to
94.9%]. Median PFS was 4.8 months (95% CI 1.8–6.9 months),
and 6-month PFS was 35.9% (95% CI 20.0% to 51.8%). Of note,
the 2-month PFS rate was 62.2%, which did not differ significantly
from the null value of 50% (one-sided P = 0.063). Kaplan–Meier
curves for PFS and overall survival are shown in Figures 2 and 3,
respectively.
tolerability and toxicity
Dasatinib was generally well tolerated by most patients. The
median and total number of cycles administered in the ACC
cohort were 3 and 158, respectively, and the median and total
number in the non-ACC group were 2 and 40, respectively.
Fatigue was the most common toxicity associated with dasatinib
occurring in over half of the patients (Table 2). Severe fatigue
however was reported in about 7% of patients (Table 3). Nausea
and headaches were the next most common side-effects but
also were lower grade and severe only in a small percentage
of patients (<5%). Grade 3/4 dyspnea occurred in 9.3% of the
patients. The majority of other toxicities associated with dasati-
nib were primarily low grade. Serious AEs at least possibly
related to dasatinib were: noncardiac chest pain (grade 2),
loss of vision (grade 4), anorexia (grade 2), hyperglycemia
(grade 2), urticarial (grade 2), dyspnea (grade 3), nausea
(grade 3), hypoxia (grade 3), alanine aminotransferase increased
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Figure 1. Maximum objective changes in tumor size from before treatment
in response to dasatinib for adenoid cystic carcinoma. In addition to the
above tumor size changes, four patients developed new lesions, one patient
had unequivocal progression of nontarget lesions, three patients had clinical
disease progression, seven patients had adverse events and were removed
from therapy, one died and three withdrew from the trial before the first
disease evaluation.
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Figure 3. Kaplan–Meier curve showing overall survival. Vertical tics indi-
cated censored observations.
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Figure 2. Kaplan–Meier curve showing progression-free survival. Vertical
tics indicated censored observations.
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(grade 2), and dyspnea (grade 3) occurring in eight (14.8%)
patients.
discussion
To date ACC remains a subtype of salivary gland cancer in
which advancement of clinical outcome has been elusive. Chief
among these obstacles for managing this cancer is the high rate
of local and distant tumor progression. These clinical features in
combination with the high incidence of cKIT amplification,
heightens the attractiveness for utilizing cKIT as a therapeutic
target for treating ACC. This strategy has been successfully
demonstrated in several tumor models including CML, GIST,
and melanoma.
Our strategy for examining the activity of dasatinib took into
consideration prior attempts by other investigators to target
cKIT in ACC. We speculated that, compared with imatinib, the
heightened inhibitory effect of dasatinib on cKIT tyrosine
kinase activity and broadened effects against other targeted
pathways would significantly improve the likelihood of assessing
antitumor effects cKIT inhibition. The trial design applied an
enrichment strategy to improve the sensitivity to detect tumor
response by selecting patients with cKIT overexpressing tumors
and by utilizing a high level of stringency for patient selection
that excluded patients with indolent tumors. However, our ob-
servation that only one patient experienced significant objective
tumor response indicates that cKIT is an inactive target in ACC.
In agreement with this observation is evidence indicating that
cKIT mutations in ACC are not functionally active [17]. Some
patients experienced prolonged disease stability. It is possible
that this could represent minor activity related to other pathways
by which dasatinib is known to exert its inhibitory antitumor
growth effects. Such effects however are perhaps insufficient to
warrant further examination of this agent in this disease.
A potential limitation of early phase clinical trials of targeted
agents is that the use of traditional study end points that may
fail to detect clinical activity of drugs [18, 19]. This constraint is
conceivably heightened in diseases that are characterized by
slow tumor growth rate. The use of alternative study end points
(such as tumor specific markers, functional imaging, time to
progression) for cytostatic molecular targeted agents has been
suggested to improve the sensitivity of detecting clinical activity
of new drugs [19]. Our observation of median PFS 19.2 weeks
and 6-month PFS 35.9% in ACC patients compares favorably to
that observed by Liu et al (median PFS 10 weeks, and 6-month
PFS 12.5% (95% CI 3.4% to 45.7%). This contrast may be more
meaningful considering that the more stringent eligibility cri-
teria in our trial selected for an ACC population with a higher
tumor growth rate and perhaps a poorer prognosis. Our obser-
vation showing that only a single ACC patient achieved clinical
response indicates that dasatinib is not a highly active drug in
this disease. However, it is conceivable that dasatinib may have
Table 2. Toxicities considered at least possibly related to dasatinib
occurring in at least 5% of patients (any grade) or grade 3/4; ACC
and non-ACC patients (N = 54)
Toxicity Any grade
No. of patients
(%)
Grade 3/4
No. of patients
(%)
Alanine aminotransferase
increased
12 (22.2) 1 (1.9)
Alkaline phosphatase increased 6 (11.1) 0
Anorexia 10 (18.5) 0
Anemia 16 (29.6) 0
Aspartate aminotransferase
increased
10 (18.5) 0
Back pain 4 (7.4) 0
Chills 3 (5.6) 0
Constipation 5 (9.3%) 0
Cough 4 (7.4%) 0
Diarrhea 17 (31.5) 0
Dizziness 3 (5.6) 1 (1.9)
Dyspnea 15 (27.8) 5 (9.3)
Edema face 5 (9.3) 0
Edema limbs 4 (7.4) 0
QTc interval prolonged 1 (1.9) 1 (1.9)
Eye disorder 2 (3.7) 2 (3.7)
Fatigue 29 (53.7) 4 (7.4)
Headache 19 (35.2) 2 (3.7)
Hyperglycemia 9 (16.7) 0
Hyperkalemia 5 (9.3) 0
Hypertension 4 (7.4) 0
Hypocalcemia 4 (7.4) 0
Hyponatremia 3 (5.6) 1 (1.9)
Hypophosphatemia 1 (1.9) 1 (1.9)
Hypoxia 1 (1.9) 1 (1.9)
Lung infection 1 (1.9) 1 (1.9)
Lymphopenia 7 (13.0) 1 (1.9)
Myalgia 4 (7.4) 0
Nausea 23 (42.6) 1 (1.9)
Neutropenia 4 (7.4) 2 (3.7)
Noncardiac chest pain 4 (7.4) 0
Oral pain 3 (5.6) 0
Platelet count decreased 6 (11.1) 0
Pleural effusion 4 (7.4) 2 (3.7)
Rash acneiform 4 (7.4) 0
Rash maculopapular 11 (20.4) 0
Rash/dermatitis 5 (9.3) 0
Vomiting 10 (18.5) 1 (1.9)
White blood cell count decreased 3 (5.6) 1 (1.9)
Table 3. Summary of grade 3/4 AEs at least possibly related to
dasatinib ACC and non-ACC patients (N = 54)
Toxicity No. of patients (%)
Fatigue 4 (7.4)
Headache 2 (3.7)
Neutropenia 2 (3.7)
Dyspnea 5 (9.3)
Lung infection 1 (1.9)
Nausea 1 (1.9)
Dizziness 1 (1.9)
Lymphopenia 1 (1.9)
Vomiting 1 (1.9)
White blood cell decreased 1 (1.9)
ECG QT-corrected interval prolonged 1 (1.9)
Eye disorder (loss of vision) 1 (1.9)
Pleural effusion 1 (1.9)
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some minor clinical activity in ACC. Our observation of no
clinical responses to dasatinib in the non-ACC population like-
wise suggests absence of significant clinical activity. Similar
arguments can be made about the limitations of these data that
may be constrained by the trial design.
We conclude that dasatinib is tolerable but has no significant
activity in ACC or non-ACC MSGT. Our findings underscore
the need for future trials to examine molecular underpinnings
of MSGTs and additional studies that examine targeted therapy
approaches for treatment of this disease.
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